title: A comparative phosphoproteomic analysis of a human tumor metastasis model using a label-free quantitative approach.
abstract: Alterations in cellular phosphorylation patterns have been implicated in a number of diseases, including cancer, through multiple mechanisms. Herein we present a survey of the phosphorylation profiles of an isogenic pair of human cancer cell lines with opposite metastatic phenotype. Phosphopeptides were enriched from tumor cell lysates with titanium dioxide and zirconium dioxide, and identified with nano-LC-MS/MS using an automatic cross-validation of MS/MS and MS/MS/MS (MS2+MS3) data-dependent neutral loss method. A spectral counting quantitative strategy was applied to the two cell line samples on the MS2-only scan, which was implemented successively after each MS2+MS3 scan in the same sample. For all regulated phosphopeptides reported by spectral counting analysis, sequence and phosphorylation site assignments were validated by a MS2+MS3 data-dependent neutral loss method. With this approach, we identified over 70 phosphorylated sites on 27 phosphoproteins as being differentially expressed with respect to tumor cell phenotype. The altered expression levels of proteins identified by LC-MS/MS were validated using Western blotting. Using network pathway analysis, we observed that the majority of the differentially expressed proteins were highly interconnected and belong to two major intracellular signaling pathways. Our findings suggest that the phosphorylation of isoform A of lamin A/C and GTPase activating protein binding protein 1 is associated with metastatic propensity. The study demonstrates a quantitative and comparative proteomics strategy to identify differential phosphorylation patterns in complex biological samples.
authors.affiliation: Department of Surgery, University of Michigan Medical Center, Ann Arbor, MI 48109-0656, USA.
authors.forename: Xiaolei
authors.initials: X
authors.lastname: Xie
authors.forename: Shun
authors.initials: S
authors.lastname: Feng
authors.forename: Huy
authors.initials: H
authors.lastname: Vuong
authors.forename: Yashu
authors.initials: Y
authors.lastname: Liu
authors.forename: Steve
authors.initials: S
authors.lastname: Goodison
authors.forename: David M
authors.initials: DM
authors.lastname: Lubman
mesh_terms: D015153:Blotting, Western; D001943:Breast Neoplasms / Q000737:chemistry* / Q000378:metabolism / Q000473:pathology*; D045744:Cell Line, Tumor; D016000:Cluster Analysis; D006801:Humans; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis* / Q000378:metabolism; D010446:Peptide Fragments / Q000032:analysis / Q000378:metabolism; D010641:Phenotype; D010750:Phosphoproteins / Q000032:analysis* / Q000378:metabolism; D010766:Phosphorylation; D040901:Proteomics / Q000379:methods*; D015203:Reproducibility of Results; D015398:Signal Transduction; D053719:Tandem Mass Spectrometry / Q000379:methods*; D014025:Titanium / Q000737:chemistry; D015040:Zirconium / Q000737:chemistry
chemical_list: D009363:Neoplasm Proteins; D010446:Peptide Fragments; D010750:Phosphoproteins; C009495:titanium dioxide; D015040:Zirconium; D014025:Titanium; C028541:zirconium oxide
references.citation: J Proteome Res. 2006 Sep;5(9):2339-47
references.pmid: 16944946
references.citation: Proc Natl Acad Sci U S A. 1980 Mar;77(3):1311-5
references.pmid: 6246487
references.citation: Cell. 2007 Dec 14;131(6):1190-203
references.pmid: 18083107
references.citation: Biochim Biophys Acta. 2008 Feb;1784(2):276-84
references.pmid: 18082151
references.citation: Clin Cancer Res. 2002 Jan;8(1):61-74
references.pmid: 11801541
references.citation: Anal Chem. 2007 Feb 15;79(4):1301-10
references.pmid: 17297928
references.citation: Exp Mol Pathol. 2007 Feb;82(1):85-90
references.pmid: 17046747
references.citation: J Proteome Res. 2008 Nov;7(11):4727-35
references.pmid: 18808171
references.citation: J Proteome Res. 2008 Apr;7(4):1640-9
references.pmid: 18314942
references.citation: Cell. 2006 Nov 3;127(3):635-48
references.pmid: 17081983
references.citation: Anal Chem. 2004 Jul 15;76(14):4193-201
references.pmid: 15253663
references.citation: J Cell Mol Med. 2008 Jan-Feb;12(1):209-18
references.pmid: 18053086
references.citation: J Med Genet. 2005 Mar;42(3):214-20
references.pmid: 15744034
references.citation: Am J Pathol. 2005 May;166(5):1565-79
references.pmid: 15855655
references.citation: Mol Cell Proteomics. 2005 Sep;4(9):1265-72
references.pmid: 15958392
references.citation: J Proteome Res. 2008 Jan;7(1):51-61
references.pmid: 18173218
references.citation: Cancer Res. 2005 Jul 15;65(14):6042-53
references.pmid: 16024604
references.citation: Proc Natl Acad Sci U S A. 2006 Dec 12;103(50):18928-33
references.pmid: 17138671
references.citation: Mol Cell Proteomics. 2008 Jan;7(1):71-87
references.pmid: 17872894
references.citation: Mol Cell Biol. 2001 Nov;21(22):7747-60
references.pmid: 11604510
references.citation: Expert Rev Anticancer Ther. 2008 Oct;8(10):1689-98
references.pmid: 18925859
references.citation: J Proteome Res. 2007 Nov;6(11):4150-62
references.pmid: 17924679
references.citation: Mol Cell Proteomics. 2006 Oct;5(10):1799-810
references.pmid: 16844681
references.citation: Cell Mol Life Sci. 2004 Jun;61(12):1475-84
references.pmid: 15197471
references.citation: Eur J Cell Biol. 1993 Dec;62(2):237-47
references.pmid: 7925482
references.citation: Proteomics. 2004 Sep;4(9):2754-65
references.pmid: 15352249
references.citation: Breast Cancer Res. 2007;9(4):211
references.pmid: 17705881
references.citation: Mol Cell Proteomics. 2005 Oct;4(10):1487-502
references.pmid: 15979981
references.citation: Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3808-14
references.pmid: 14506175
references.citation: Mol Cell Proteomics. 2009 Jun;8(6):1436-49
references.pmid: 19321434
references.citation: Cancer Res. 2002 Mar 1;62(5):1251-5
references.pmid: 11888885
references.citation: J Proteome Res. 2009 Mar;8(3):1168-82
references.pmid: 19178300